Koers Onconova Therapeutics Inc Nasdaq
Aandelen
US68232V1089
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 210K 194K | Omzet 2025 * | 300K 278K | Marktkapitalisatie | 16,45 mln. 15,23 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,3 mln. | Nettowinst (verlies) 2025 * | -28 mln. -25,93 mln. | EV/omzet 2024 * | 78,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 54,8 x |
K/w-verhouding 2024 * |
-0,75
x | K/w-verhouding 2025 * |
-0,78
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,39% |
Recentste transcriptie over Onconova Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19-01-15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01-09-13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01-07-15 |
Jack Stover
BRD | Director/Board Member | 69 | 23-05-16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01-04-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,85% | 57,87 mld. | |
+41,42% | 40,25 mld. | |
-5,25% | 39,94 mld. | |
-5,16% | 28,54 mld. | |
+12,79% | 26,4 mld. | |
-20,18% | 19,33 mld. | |
+30,88% | 12,4 mld. | |
+0,61% | 12,23 mld. | |
+25,06% | 12,2 mld. |